Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleolar GTP-binding protein 2 (GNL2) is a nucleolar-localized GTPase that binds RNA and associates with pre-60S ribosomal subunits, facilitating their nuclear export and maturation. It plays a critical role in ribosome biogenesis and protein synthesis, and is implicated in the regulation of cell proliferation via modulation of p53/TP53 and downstream proteins. GNL2 acts as an oncogene in several cancers, most notably glioma, with high expression correlating with decreased patient survival. Functional studies show GNL2 silencing impairs cell proliferation, invasion, migration, ribosomal subunit export, and overall protein synthesis, highlighting its potential as a therapeutic target and biomarker in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleolar GTP-binding protein 2 (GNL2).